IMPACT Silver Revenue Doubles, Beam Global Posts 174% Sequential Surge in Q2 2026 Earnings

The Quick Take

• IMPACT Silver Corp (ISVLF) revenue surges 124% in Q2 2026 as higher silver prices drive mining profitability.
• Beam Global (BEEM) reports 174% sequential and 21% year-over-year revenue increase on European and defense demand.
• India's Orchid Pharma posts EBITDA more than doubling to INR 25 crore on Exblifep antibiotic volume growth.

IMPACT Silver Corporation's Q2 2026 earnings highlight the powerful leverage that mining companies carry to commodity price cycles. Revenue nearly doubling on a 124% year-over-year basis reflects both silver price appreciation and operational output, and the company's strong balance sheet with over $50 million in cash positions it for aggressive exploration or M&A during the current metals cycle. Silver's persistent supply deficit makes this an unusually capital-advantaged moment.

Beam Global's Q2 performance tells a story of rapid top-line recovery: sequential revenue surged 174%, translating to 21% year-over-year growth as the company's EV charging and energy storage solutions gained traction in European markets and defense applications. The two-pronged commercial strategy spanning civilian EV infrastructure and military-grade energy systems provides a rare combination of ESG-driven and defense-driven revenue streams attracting capital from multiple investor categories.

Orchid Pharma's contribution underscores India's pharmaceutical sector momentum. EBITDA more than doubling to INR 25 crore in Q1 FY2027 was driven by robust Exblifep volume growth, with the beta-lactamase inhibitor antibiotic generating strong export demand. Gross margin improvement alongside revenue gains demonstrates that Orchid's product mix is shifting favorably toward higher-value specialty generics, a positive trajectory for Indian pharma investors.

Synthesized from 4 sources — full coverage, sentiment breakdown, and forward signals below.